Open Access

Publisher Correction: Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients

BMC NephrologyBMC series – open, inclusive and trusted201718:306

https://doi.org/10.1186/s12882-017-0716-1

Received: 18 September 2017

Accepted: 18 September 2017

Published: 4 October 2017

The original article was published in BMC Nephrology 2017 18:251

Erratum

In the original publication of this article [1], Table 3 is incorrect, several cell values in column 4 (no ESA (n = 8)) have been incorrectly shifted during typesetting.

In this Erratum the correct and incorrect version of Table 3 are published.

The publisher apologizes for the inconvenience caused by this error to the authors and readers.

Table 1

Incorrect version of Table 3 as published on 26 July 2017. The incorrect cells are displayed in italics

 

Hb >10 g/dL

Hb ≤10 g/dL

p-value

no ESA (n = 63)

ESA ≤40 μg/w (n = 75)

ESA >40 μg/w (n = 41)

no ESA (n = 8)

ESA ≤40 μg/w (n = 25)

ESA >40 μg/w (n = 28)

Age (years)

67.8 ± 15.3

67.1 ± 16.2

69.9 ± 15.4

74.5 ± 8.1

64.8 ± 17.6

65.9 ± 18.3

0.63

Gender (male)

61.9%

58.7%

41.5%

62.5%

64.0%

42.9%

0.19

Diabetes

44.4%

41.3%

43.9%

37.5%

48.0%

35.7%

0.96

Hemoglobin (g/dL)

11.6 ± 0.9

11.2 ± 0.8

11.1 ± 0.8

9.6 ± 0.6

9.5 ± 0.4

9.0 ± 0.9

<0.001

TSAT (%)

29.2 ± 13.5

23.5 ± 9.2

22.7 ± 11.1

45.8 ± 27.4

25.6 ± 9.8

20.1 ± 17.4

<0.001

Ferritin (ng/mL)

480 ± 330

426 ± 285

473 ± 304

1341 ± 1541

636 ± 314

677 ± 901

<0.001

Albumin (g/L)

38.4 ± 4.4

39.2 ± 4.1

37.5 ± 4.8

 

37.8 ± 4.6

33.0 ± 7.8

<0.001

β2 microglobulin (mg/L)

26.2 ± 7.0

25.7 ± 6.9

27.4 ± 8.2

34.1 ± 6.4

25.6 ± 6.2

27.4 ± 7.0

0.008

Parathormone (pg/mL)

268 ± 318

284 ± 315

195 ± 207

35.8 ± 9.8

264 ± 354

237 ± 438

0.83

Predialysis creatinine (μmol/L)

764 ± 282

769 ± 242

684 ± 250

224 ± 299

757 ± 220

638 ± 239

0.08

Predialysis urea (mmol/L)

20.8 ± 5.9

21.7 ± 6.7

20.0 ± 6.5

623 ± 153

21.0 ± 6.1

19.6 ± 8.3

0.39

C-reactive protein (mg/L)

12.2 ± 18.9

12.7 ± 28.4

26.0 ± 67.4

17.2 ± 5.5

23.1 ± 49.9

36.5 ± 37.1

0.02

IAA (μmol/L)

5.10 ± 5.28

5.73 ± 5.97

3.51 ± 3.50

51.9 ± 97.3

4.67 ± 3.05

3.78 ± 2.60

0.09

IS (μmol/L)

92.8 ± 54.7

97.9 ± 45.2

100.9 ± 49.9

2.29 ± 1.30

85.2 ± 55.5

82.3 ± 61.9

0.54

PCS(μmol/L)

169 ± 101

172 ± 94

150 ± 97

78.1 ± 37.6

175 ± 98

96 ± 99

0.01

Iron medication

 IV iron medication

54.0%

68.0%

73.2%

135 ± 75

48.0%

64.3%

0.10

 Iron dose (mg/mo)

175 ± 188

228 ± 245

351 ± 318

163 ± 292

124 ± 167

314 ± 374

0.002

HDF (%)

54.0%

30.7%

31.7%

50.0%

52.0%

46.4%

0.05

Kt/V

1.51 ± 0.26

1.50 ± 0.28

1.50 ± 0.42

1.46 ± 0.30

1.57 ± 0.26

1.51 ± 0.34

0.95

Table 2

Correct version of Table 3, the corrected cells are displayed in bold

 

Hb >10 g/dL

Hb ≤10 g/dL

p-value

no ESA (n = 63)

ESA ≤40 μg/w (n = 75)

ESA >40 μg/w (n = 41)

no ESA (n = 8)

ESA ≤40 μg/w (n = 25)

ESA >40 μg/w (n = 28)

Age (years)

67.8 ± 15.3

67.1 ± 16.2

69.9 ± 15.4

74.5 ± 8.1

64.8 ± 17.6

65.9 ± 18.3

0.63

Gender (male)

61.9%

58.7%

41.5%

62.5%

64.0%

42.9%

0.19

Diabetes

44.4%

41.3%

43.9%

37.5%

48.0%

35.7%

0.96

Hemoglobin (g/dL)

11.6 ± 0.9

11.2 ± 0.8

11.1 ± 0.8

9.6 ± 0.6

9.5 ± 0.4

9.0 ± 0.9

<0.001

TSAT (%)

29.2 ± 13.5

23.5 ± 9.2

22.7 ± 11.1

45.8 ± 27.4

25.6 ± 9.8

20.1 ± 17.4

<0.001

Ferritin (ng/mL)

480 ± 330

426 ± 285

473 ± 304

1341 ± 1541

636 ± 314

677 ± 901

<0.001

Albumin (g/L)

38.4 ± 4.4

39.2 ± 4.1

37.5 ± 4.8

34.1 ± 6.4

37.8 ± 4.6

33.0 ± 7.8

<0.001

β2 microglobulin (mg/L)

26.2 ± 7.0

25.7 ± 6.9

27.4 ± 8.2

35.8 ± 9.8

25.6 ± 6.2

27.4 ± 7.0

0.008

Parathormone (pg/mL)

268 ± 318

284 ± 315

195 ± 207

224 ± 299

264 ± 354

237 ± 438

0.83

Predialysis creatinine (μmol/L)

764 ± 282

769 ± 242

684 ± 250

623 ± 153

757 ± 220

638 ± 239

0.08

Predialysis urea (mmol/L)

20.8 ± 5.9

21.7 ± 6.7

20.0 ± 6.5

17.2 ± 5.5

21.0 ± 6.1

19.6 ± 8.3

0.39

C-reactive protein (mg/L)

12.2 ± 18.9

12.7 ± 28.4

26.0 ± 67.4

51.9 ± 97.3

23.1 ± 49.9

36.5 ± 37.1

0.02

IAA (μmol/L)

5.10 ± 5.28

5.73 ± 5.97

3.51 ± 3.50

2.29 ± 1.30

4.67 ± 3.05

3.78 ± 2.60

0.09

IS (μmol/L)

92.8 ± 54.7

97.9 ± 45.2

100.9 ± 49.9

78.1 ± 37.6

85.2 ± 55.5

82.3 ± 61.9

0.54

PCS(μmol/L)

169 ± 101

172 ± 94

150 ± 97

135 ± 75

175 ± 98

96 ± 99

0.01

Iron medication

 IV iron medication

54.0%

68.0%

73.2%

37.5%

48.0%

64.3%

0.10

 Iron dose (mg/mo)

175 ± 188

228 ± 245

351 ± 318

163 ± 292

124 ± 167

314 ± 374

0.002

HDF (%)

54.0%

30.7%

31.7%

50.0%

52.0%

46.4%

0.05

Kt/V

1.51 ± 0.26

1.50 ± 0.28

1.50 ± 0.42

1.46 ± 0.30

1.57 ± 0.26

1.51 ± 0.34

0.95

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)

Reference

  1. Bataille, et al. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrol. 2017;18:251. doi: 10.1186/s12882-017-0668-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement